Novo Nordisk

Novo Nordisk goes for broke on semaglutide heart data
Novo Nordisk goes for broke on semaglutide heart data
Biopharma Dive
Novo Nordisk
diabetes
FDA
Ozempic
oral semaglutide
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Pharmaforum
Novo Nordisk
type 2 diabetes
diabetes
chronic kidney disease
Flag link:
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug
Motley Fool
Novo Nordisk
earnings
diabetes
oral semaglutide
FDA
Flag link:
Renewable Energy Will Power all of Novo Nordisk’s Production Facilities by 2020
Renewable Energy Will Power all of Novo Nordisk’s Production Facilities by 2020
BioSpace
Novo Nordisk
drug manufacturing
renewable energy
environmental concerns
Flag link:
Novo seeks Victoza label expansion with fresh pediatric trial results
Novo seeks Victoza label expansion with fresh pediatric trial results
Biopharma Dive
Novo Nordisk
type 2 diabetes
pediatrics
Victoza
Flag link:
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
TheStreet.com
NASH
Gilead Sciences
Novo Nordisk
clinical trials
Flag link:
Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk seeks FDA nod for oral diabetes pill
Drug Delivery Business News
Novo Nordisk
FDA
semaglutide
diabetes
Flag link:
Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva
Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva
Pharmaceutical Business Review
Novo Nordisk
Teva Pharmaceutical
patents
Victoza
diabetes
Flag link:
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Fierce Pharma
Novo Nordisk
diabetes
Teva Pharmaceutical
Victoza
semaglutide
Flag link:
Novo Nordisk Launches Innovation Platform in China
Novo Nordisk Launches Innovation Platform in China
CP Wire
Novo Nordisk
China
innovation
Innovo
Flag link:
Novo Nordisk Launches Innovation Platform in China
Novo Nordisk
China
Flag link:
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
Endpoints
Novo Nordisk
Trulicity
Ozempic
Eli Lilly
diabetes
Flag link:
Abbott, Novo Nordisk ink deal for digital diabetes tools
Abbott, Novo Nordisk ink deal for digital diabetes tools
Drug Delivery Business News
Abbott Labs
Novo Nordisk
digital health
digital pharma
insulin
diabetes
FreeStyle Libra
devices
connected insulin pen
Flag link:
IP trouble defers launch of Novo's long-acting hemophilia therapy
IP trouble defers launch of Novo's long-acting hemophilia therapy
Endpoints
Novo Nordisk
Eseproct
hemophilia
Roche
Hemlibra
Flag link:
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
BioSpace
obesity
Sanofi
Novo Nordisk
AstraZeneca
Flag link:
An oral insulin delivery system inspired by tortoises
An oral insulin delivery system inspired by tortoises
Fierce Biotech
diabetes
insulin
drug delivery
MIT
Brigham and Women's
Novo Nordisk
OI388GT
Flag link:
Mark Your Calendar For These February PDUFA Dates
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Flag link:
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing
Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing
BioSpace
earnings
Pfizer
Amgen
AbbVie
JNJ
Merck
Novo Nordisk
Takeda
Flag link:
Novo bets on swift FDA review for oral diabetes drug semaglutide
Novo bets on swift FDA review for oral diabetes drug semaglutide
Endpoints
Novo Nordisk
earnings
semaglutide
FDA
Flag link:

Pages